AUTHOR INDEX

(P = proceedings)

AARONS, L. Population pharmacokinetics: theory and practice, 669
ABUIRJEIE, M. A. *see* IRSHAID, Y. M.
ADVENIER, C. *see* NALINE, E.
ADVENIER, C. *see* SPREUX-VAROQUAUX, O.
AHMED, J. H., GRANT, A. C., RODGER, R. S. C., MURRAY, G. R. & ELLIOTT, H. L. Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine, 57
AITCHISON, T. *see* GRANT, S.
AL-HADIDI, H. F. *see* IRSHAID, Y. M.
AL-LANQAWI, MORELAND, T. A., OGG, G. D., TREGASKIS, B., MCEWEN, J. & STEVENSON, I. H. Ethanol pharmacokinetics—reproducibility in volunteer subjects, 656P
ALFORD, C., BHATTI, J. Z., CURRAN, S., MCKAY, G. & HINDMARCH, I. Pharmacodynamic effects of buspirone and clobazam, 91
ALLEN, R. *see* THOMAS, S. H. L.
ANDERSSON, T. *see* OOSTERHUIS, B.
ANDREW, P. D., MURKITT, G. S., MILLSON, D. S., PALMER, J. L. & THOMAS, M. The determination of GR 68755 in plasma and its pharmacokinetic profile in human volunteers, 668P
ANDRIEU, J. *see* SPREUX-VAROQUAUX, O.
ANGELIN, B. *see* HEDMAN, A.
APARICIO, M. *see* FILLASTRE, J. P.
ARMITAGE, P. Should we cross off the crossover?, 1
ARNOLD, B. D. C. *see* HUCKER, R. S
ARONSON, J. K. Book review: Clinical chronopharmacology. Concepts, kinetics, application, 263
ARONSSON, J. K. *see* MORAES, M. E. A.
ARVIDSSON, A. *see* HEDMAN, A.

BAASCH, H. *see* TARTARA, A.
BABER, N. S. *see* SCIBERRAS, D. G.
BACK, D. J. & TJIA, J. F. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terninifine on the metabolism of cyclosporin by human liver microsomes, 624
BACK, D. J. *see* NA BANGCHANG, K.
BACK, D. J. *see* SIM, S. M.
BACKON, J. & HOFFMAN, A. Letter to the Editor: The lateral decubitus position may affect gastric emptying through an autonomic mechanism: the pressure-vegetative reflex, 138
BAILEY, D. *see* CUNNINGHAM, V. J.
BAINBRIDGE, A. D. *see* MACFADYEN, R. J.
BAKDACH, H. *see* NALINE, E.
BALLARDIE, F. W. *see* EDWARDS, B. D.
BARKER, R. C. *see* PARK, Y. H.
BARNARD, S., PARK, B. K. & STORR, R. C. Effect of fluorine substitution on the hepato-toxicity of paracetamol, 651P
BARRETT, D. A., ELIAS-JONES, A. C., RUTTER, N., SHAW, P. N. & DAVIS, S. S. Morphine kinetics after diamorphine infusion in premature neonates, 31
BARROW, S. E., STRATTON, P. D., BENJAMIN, N., BRASSFIELD, T. & RITTER, J. M. Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolaemia at risk of coronary heart disease, 127
BARZAGHI, N. *see* TARTARA, A.
BATEMAN, D. *see* CUNNINGHAM, V. J.
BATEMAN, D. N. *see* ISAH, A. O.
BEARD, M. *see* WEBSTER, J.
BEERAHEE, A., BULLMAN, J. N., DOYLE, E., KAYE, C. M., MEAD, E. A., TAYLOR, A. C. & UNDRE, N. A. An improved analytical method for the specific assay of BRL 38227 in human plasma and urine by h.p.l.c. with fluorescence detection, 656P
BÉGAUD, B. *see* TUBERET, P.
BELCH, J. J. F. *see* DAWES, J.
BENJAMIN, M., RYMER, J., TODD, S. D., THOM, M. & RITTER, J. M. Sensitivity to angiotensin II of forearm resistance vessels in pregnancy, 523
BENJAMIN, N. *see* BARROW, S. E.
BENJAMIN, N. *see* WOOLFSON, R. G.
BENNETT, A. *see* RILEY, S. A.
BENNETT, P. N. *see* OLIVER, S. E.
BERGMANN, H. *see* STACHER, G.
BERNARD, N. *see* FERRY, N.
BERSON, A. *see* TINEL, M.
BESWICK, P. H. *see* CLAPPERTON, M.
BETTERIDGE, J. D. *see* JAY, R. H.
BETTS, T., HARRIS, D. & GADD, E. The effects of two anti-vertigo drugs (betahistine and prochlorperazine) on driving skills, 455
BHASKAR, N. K. *see* RIMOY, G. H.
BHASKAR, N. K. *see* WRIGHT, D. M.
BHATTI, J. Z. *see* ALFORD, C.
BIRKELAND, K. *see* GULLESTAD, L.
BIRKETT, D. J., MINERS, J. O. & DAY, R. O. 1-methylxanthine derived from theophylline as an *in vivo* biochemical probe of allopurinol effect, 238
BISHAI, P. M. *see* RILEY, S. A.
BLACKLAW, J. *see* MCKEE, P. J.
BLACKLAW, J. *see* MCKEE, P. J. W.
BLIN, O., MESTRE, D., MASSON, G. & SERRATRICE, G. Selective effects of low doses of apomorphine on spatiotemporal contrast sensitivity in healthy volunteers: a double-blind placebo-controlled study, 551
BLOUIN, R. A. *see* SMITH, D. A.
BLYCHERT, E. *see* WAITE, M. A.
BONE, M. E. *see* WAITE, M. A.
BORBE, H. O. *see* HUMMEL, T.
BOWDLER, D. A. *see* HOLDING, J. D.
BRADBURY, A., COZENS, S. J., EVANS, D. C., MILLSON, D. S. & THOMAS, M. The disposition of GR 68755 after oral administration to man, 654P
BRASSFIELD, T. *see* BARROW, S. E.
BRAY, B. *see* DAWES, J.
BRAZZELL, R. K. *see* PARK, Y. H.
BRECKENRIDGE, A. M. *see* NG, H. W. K.
BRECKENRIDGE, A. M. *see* PIRMOHAMED, M.
BRECKENRIDGE, A. M. *see* SCOTT, A. K.
BRECKENRIDGE, A. M. *see* SIM, S. M.
BREIMER, D. D. *see* DE BOER, A.
BREIMER, D. D. *see* SOONS, P. A.
BRENNAN, G. M., MCVEIGH, G. E., JOHNSTON, G. D., HAYES, J. R. & MCDERMOTT, B. J. Impaired endothelium-dependent and independent responses in non-insulin dependent diabetes mellitus, 648P
BRITTO, M. R., MCKEAN, H. E., BRUCKNER, G. G. & WEDLUND, P. J. Polymorphism in oxidative drug metabolism: relationship to food preference, 235
BRODDE, O.-E. *see* MICHEL, M. C.
BRODIE, M. J. *see* MCKEE, P. J.
BROLY, F., VANDAMME, N., LIBERSA, C. & LHERMITTE, M. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation, 459
BRØSEN, K. & SKJELBO, E. Letter to the Editors: Fluoxetine and norfluoxetine are potent inhibitors of P450IID6—the source of the sparteine/debrisoquine oxidation polymorphism, 136
BROWN, M. J. *see* SHAWKET, S.
BROYARD, J. P. *see* MURA, C.
BRUCKNER, G. G. *see* BRITTO, M. R.
BRUGUIER, M. *see* FERRY, N.
BUCHANAN, N. *see* PENNA, A.
BULLMAN, J. N. *see* BEERAHEE, A.
BUNNAG, D. *see* NA BANGCHANG, K.
BUNTINX, A. *see* DUPONT, A. G.
BURCKART, G. J. *see* SCHWINGHAMMER, T. L.
BURGESS, E. Letter to the Editors:

Aluminium absorption following sucralfate therapy, 641
BURM, A. G. L. *see* VEERING, B. Th.
BUSATO, E. *see* LIBARDONI, M.
BUTLER, E. *see* MCKEE, P. J. W.
BYE, A. *see* NICHOLS, D. J.
BYROM, H., CLARK, M., WHITE, V. & VERE, D. W. The basis of the histamine assay in skin, 367

CAMBIUCCI, E. C. *see* CONDINO-NETO, A.
CAPEWELL, S. *see* DEARY, I. J.
CARBONI, G. P., SCARDOVI, A. B., D'ERMO, M. & PRATI, P. L. Bopindolol in chronic stable angina pectoris: duration and extent of antianginal actions, 755
CARESIA, L. *see* TARTARA, A.
CATTONI, M. P. *see* TINEL, M.
CELSIS, P. *see* SABATINI, U.
CHADWICK, D. *see* PIRMOHAMED, M.
CHALCROFT, S. *see* WANWIMOLRUK, S.
CHAN-LAM, J. M. D. *see* MCGOVERN, E. M.
CHANDLER, M. H. H. *see* SMITH, D. A.
CHANNER, K. S. The drug treatment of atrial fibrillation, 267
CHARTER, M. K. *see* THOMAS, M.
CHASSEAUD, L. F. *see* TAYLOR, I. W.
CHEAH, L. S. *see* GWEE, M. C. E.
CHIBA, K. *see* SOHN, D.-R.
CHILTON, J. E. *see* THOMAS, M.
CHOUDRY, N. B., GRAY, S. J., POSNER, J. & FULLER, R. W. The effect of 443C81, a μ opioid receptor agonist, on the response to inhaled capsaicin in healthy volunteers, 633
CHRISTIE, J. *see* MCMURRAY, J.
CHRYSTYN, H. *see* PULLAR, T.
CLAPPERTON, M., MCMURRAY, J., BESWICK, P. H., FISHER, A. C. & DARGIE, H. J. ACE inhibitors reduce free radical production, *ex vivo*, by human neutrophils, 662P
CLARK, K. L. *see* THOMAS, S. H. L.
CLARK, M. *see* BYROM, H.
COHEN, A. F. *see* SOONS, P. A.
COLE, A. T. *see* HAWTHORNE, A. B.
COLEMAN, J. *see* WALLEY, T.
COLEMAN, M. D. *see* PIRMOHAMED, M.
COLEMAN, M. D. *see* TINGLE, M. D.
CONDINO-NETO, A., VILELA, M. M. S., CAMBIUCCI, E. C., RIBEIRO, J. D., GUGLIELMI, A. A. G., MAGNA, L. A. & DE NUCCI, G. Theophylline therapy inhibits neutrophil and mononuclear cell chemotaxis from chronic asthmatic children, 557
CONWAY, E. L. *see* MCNEIL, J. J.
CORDONNIER, P. *see* SPREUX-VAROQUAUX, O.
COZENS, S. J. *see* BRADBURY, A.
CRAIG, K. *see* TAVERNER, D.
CREWE, H. K., LENNARD, M. S., TUCKER, G. T., WOODS, F. R. & HADDOCK, R. E. The effect of paroxetine and other specific 5-HT re-uptake inhibitors on cytochrome P450IID6 activity in human liver microsomes, 659P
CRICHTON, W. *see* WEBSTER, J.
CUISINAUD, G. *see* FERRY, N.
CUNNINGHAM, V. J., PIKE, V. W., BAILEY, D., FREEMANTLE, C. A. J., PAGE, B. C., JONES, A. K. P., KENSETT, M. J., BATEMAN, D., LUTHRA, S. K. & JONES, T. A method of studying pharmacokinetics in man at picomolar drug concentrations, 167
CURRAN, S. *see* ALFORD, C.
CURRIE, D. *see* MCDEVITT, D. G.

D'ERMO, M. *see* CARBONI, G. P.
DAHLQVIST, R. *see* HEDMAN, A.
DANHOF, M. *see* DE BOER, A.
DARGIE, H. J. *see* CLAPPERTON, M.
DARGIE, H. J. *see* GRANT, S.
DARGIE, H. J. *see* MCMURRAY, J.
DARGIE, H. J. *see* NORTHRIDGE, D. B.
DARRAGH, A. *see* TAYLOR, I. W.
DAVEY, N. B. *see* WAITE, M. A.
DAVIES, B. E. *see* HUCKER, R. S.
DAVIES, T. M. E. *see* SILAMUT, K.
DAVIS, S. S. *see* BARRETT, D. A.
DAVIS, S. S. *see* WILDING, I. R.
DAWES, J., MCLAREN, M., FORBES, C., BELCH, J. J. F., LANE, D. A., BRAY, B., MCEWEN, J., HOUIN, G. & GIANESE, F. The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers, 361
DAY, R. O. *see* BIRKETT, D. J.
DE BOER, A. *see* SOONS, P. A.
DE BOER, A., STIEKEMA, J. C. J., DANHOF, M. & BREIMER, D. D. The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172, 23
DE MEY, C., ENTERLING, D., MEINEKE, I. & YEULET, S. Interactions between domperidone and ropinirole, a novel dopamine D_2-receptor agonist, 483
DE NUCCI, G. *see* CONDINO-NETO, A.
DE SMET, M. *see* DUPONT, A. G.
DEARY, I. J., CAPEWELL, S., HAJDUCKA, C. & MUIR, A. L. The effects of captopril *vs* atenolol on memory, information processing and mood: a double-blind crossover study, 347
DENNIS, M. J. *see* SALAS-HERRARA, I. G.
DICKERSON, C. *see* SHAWKET, S.
DIEM, P. & ROBERTSON, R. P. Preventive effects of octreotide (SMS 201-995) on diabetic ketogenesis during insulin withdrawal, 563
DIXON, C. M. S. *see* IREDALE, M. J.
DIXON, J. S. *see* KHAN, A.
DOBBS, R. J., DOBBS, S. M. & WELLER, C. Clinical pharmacology, therapeutics and geriatric medicine: an interaction of importance, 405
DOBBS, S. M. *see* DOBBS, R. J.
DOLL, J. *see* SPREUX-VAROQUAUX, O.
DONNELLY, M. *see* GRANT, S.
DORF, G. *see* TAYLOR, I. W.
DOW, R. J. *see* WEBSTER, J.
DOYLE, E. *see* BEERAHEE, A.
DE BROE, M. E. *see* VERPOOTEN, G. A.
DRUMMER, O. H. *see* MCNEIL, J. J.
DUBRUC, C. *see* FILLASTRE, J. P.
DUN-REN, P. *see* LADONA, M. G.
DUPONT, A. G., IMPENS, N., SCHOORS, D. F., DE SMET, M., BUNTINX, A., MARGOLSKEE, D. J. & SCHWARTZ, J. I. Multiple dose kinetics, safety and tolerability of MK-0679, a new leukotriene (LT) D_4-receptor antagonist, 653P
DUSCI, L. J. *see* LEBEDEVS, T. H.
DUTOT, C. *see* SPREUX-VAROQUAUX, O.
DWIPRAHASTO, I. *see* MUSTOFA, M.

EDWARDS, B. D., BALLARDIE, F. W., MILLER, M. & WESTON, A. H. Letter to the Editor: Cyclosporin A does not possess K^+ channel opening properties in smooth muscle, 134
EDWARDS, C. *see* KAMALI, F.
EDWARDS, G. *see* KARBWANG, J.
EDWARDS, G. *see* MANSOR, S. M.
EIKE, O. *see* SIEGMUND, W.
ELIAS-JONES, A. C. *see* BARRETT, D. A.
ELLIOTT, H. L. *see* AHMED, J. H.
ELLIOTT, H. L. *see* GEMMILL, J. D.
ELLIOTT, H. L. *see* MACFADYEN, R. J.
ELLIOTT, H. L. *see* MACPHEE, G. J. A.
ELLIOTT, H. L. *see* SCHAFERS, R. F.
ELLIOTT, H. L., MEREDITH, P. A., MCNALLY, C. & REID, J. L. The interactions between nisoldipine and two β-adrenoceptor antagonists—atenolol and propranolol, 379
ELLMERS, S. E., PARKER, L. R., NOTARIANNI, L. J. & JONES, R. W. Does frailty influence digoxin excretion in elderly people?, 650P
ENDRENYI, L. & PATEL, M. A new, sensitive graphical method for detecting deviations from the normal distribution of drug responses: the NTV plot, 159
ENTERLING, D. *see* DE MEY, C.
EVANS, D. C. *see* BRADBURY, A.
EVANS, W. E. *see* TURGEON, J.

FACCHINI, V. *see* PAGE, K. M.
FAIRLESS, A. J. *see* FOWLES, S. E.
FARMER, K. C. *see* OLIVER, S. E.
FEELY, M. *see* PULLAR, T.
FENGLER, J. D. *see* SIEGMUND, W.

FENWICK, M. K. *see* MOTWANI, J. G.
FERNER, R. E., KAMALI, F. & RAWLINS, M. D. The effects of enalapril on dermal reactions to human calcitonin gene related peptide, 645P
FERRY, N., BERNARD, N., POZET, N., GARDES, E., BRUGUIER, M., CUISINAUD, G. & SASSARD, J. The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol, 39
FILLASTRE, J. P., APARICIO, M., PORQUET, C., DUBRUC, C., ROSENZWEIG, P. & MORSELLI, P. L. Pharmacokinetics and safety of ciclopolol in uraemic patients, 261
FISHER, A. C. *see* CLAPPERTON, M.
FORBES, C. *see* DAWES, J.
FOWLER, P. A. *see* SCOTT, A. K.
FOWLES, S. E. *see* PRATT, S. K.
FOWLES, S. E., FAIRLESS, A. J., PIERCE, D. M. & PRINCE, W. T. A further study of the effect of food on the bioavailability and pharmacokinetics of penciclovir after oral administration of famciclovir, 658P
FOX, J. S., WHITEHEAD, E. M. & SHANKS, R. G. Cardiovascular effects of cromakalin (BRL 34915) in healthy volunteers, 45
FRANKE, G. *see* SIEGMUND, W.
FREDERICKS, S. *see* LAWSON, M.
FREEMANTLE, C. A. J. *see* CUNNINGHAM, V. J.
FREESTONE, S., MCAUSLANE, J. A. N. & PRESCOTT, L. F. Effects of tenoxicam on renal function and the disposition of inulin and *p*-aminohippurate in healthy volunteers and patients with chronic renal failure, 495
FRIEDMANN, T. *see* HUMMEL, T.
FULLER, R. W. *see* CHOUDRY, N. B.

GABBY, F. J. & GOLDBERG, A. The Faculty of Pharmaceutical Medicine, 265
GABUZDA, T. *see* SHAH, J.
GADD, E. *see* BETTS, T.
GALIMBERTI, C. A. *see* TARTARA, A.
GALLOWAY, S. *see* MCMURRAY, J.
GARDES, E. *see* FERRY, N.
GATTI, G. *see* TARTARA, A.
GAUPMANN, G. *see* STACHER, G.
GEMMILL, J. D., HOWIE, C. A., MEREDITH, P. A., KELMAN, A. W., RASMUSSEN, H. S., HILLIS, W. S. & ELLIOTT, H. L. A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers, 429
GEMMILL, J. D. *see* MACFADYEN, R. J.
GENISSEL, P. M. *see* VERPOOTEN, G. A.
GEORGE, C. F. *see* WALLER, D. G.
GIANESE, F. *see* DAWES, J.
GILL, D. *see* SCIBERRAS, D. G.
GILLHAM, R. A. *see* MCKEE, P. J.
GLADINES, M. P. R. R. *see* VEERING, B. Th.
GOH, E. M. L. *see* YOUNG, J. S.
GOLDBERG, A. *see* GABBY, F. J.
GORDIN, A. *see* SUNDBERG, S.
GOTT, D. M. *see* SALAS-HERRARA, I. G.
GRAHAM, A. *see* PIRMOHAMED, M.
GRAHAME-SMITH, D. G. Clinical Pharmacology. Roles and responsibilities in academic research, 151
GRAHAME-SMITH, D. G. *see* MORAES, M. E. A.
GRANDJEAN, N. *see* SPREUX-VAROQUAUX, O.
GRANSER-VACARIU, G. V. *see* STACHER, G.
GRANT, A. C. *see* AHMED, J. H.
GRANT, S., HENDERSON, E., AITCHISON, T., DONNELLY, M., DARGIE, H. J. & MCMURRAY, J. Is there a reproducible and sensitive method of measuring symptoms during exercise in humans?, 660P
GRAY, S. J. *see* CHOUDRY, N. B.
GRAY, S. J. *see* PHILLIPS, S. C.
GRAY, S. J., ROLAN, P. E., PHILLIPS, S. C. & POSNER, J. Effect of inhalation of a novel enkephalin analogue (443C81) on the response to cold air and metabisulphite bronchial challenge in healthy volunteers, 663P
GUGLIELMI, A. A. G. *see* CONDINO-NETO, A.
GUIVARC'H, P. H. *see* LACOURCIERE, Y.
GULLESTAD, L., BIRKELAND, K., NORDBY, G., LARSEN, S. & KJEKSHUS, J. Effects of β_2-adrenoceptor blockade on serum potassium and exercise performance in normal men, 201
GWEE, M. C. E. & CHEAH, L. S. Letter to the Editor: Antimuscarinic and anticholinesterase activity of cimetidine and ranitidine: clinically significant?, 260

HACKETT, L. P. *see* LEBEDEVS, T. H.
HADDOCK, R. E. *see* CREWE, H. K.
HAJDUCKA, C. *see* DEARY, I. J.
HALE, J. P. *see* LENNARD, L.
HAMMARLUND-UDENAES, M. *see* MOVIN-OSSWALD, G.
HARAMBURU, F. *see* TUBERET, P.
HARDY, J. G. *see* WILDING, I. R.
HARINASUTA, T. *see* NA BANGCHANG, K.
HARRIGAN, J. R. & MEREDITH, P. A. Pharmacokinetic analysis of a quinapril dose ranging study: characterisation of the binding to ACE, 648P
HARRIS, D. *see* BETTS, T.
HARRY, J. *see* MILLSON, D. S.
HAWKEY, C. J. *see* HAWTHORNE, A. B.
HAWTHORNE, A. B., MAHIDA, Y. R., COLE, A. T. & HAWKEY, C. J. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis, 77
HAYES, J. R. *see* BRENNAN, G. M.
HAYNES, W. G. & WEBB, D. J. Ethics of volunteer research: the role of new EC guidelines, 671
HAZLEMAN, B. *see* SHAWKET, S.
HEDMAN, A., ANGELIN, B., ARVIDSSON, A. & DAHLQVIST, R. No effect of probenecid on the renal biliary clearances of digoxin in man, 63
HEINONEN, O. P. *see* MÄENPÄÄ, H.
HENDERSON, E. *see* GRANT, S.
HENDERSON, E. *see* MCMURRAY, J.
HENDERSON, E. *see* NORTHRIDGE, D. B.
HERD, B., WYNNE, H., WRIGHT, P., JAMES, O. & WOODHOUSE, K. The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions, 768
HIGBIE, J. W. *see* KASTRISSIOS, H.
HILLIS, W. S. *see* GEMMILL, J. D.
HILLIS, W. S. *see* MACFADYEN, R. J.
HINDMARCH, I. *see* ALFORD, C.
HIRVISALO, A. L. *see* HOPPU, K.
HO, M. *see* SILAMUT, K.
HOBART, J. *see* STACHER, G.
HOBSON, S. *see* MILLSON, D. S.
HOFFMAN, A. *see* BACKON, J.
HOLDING, J. D., LINDUP, W. E., BOWDLER, D. A., SIODLAK, M. Z. & STELL, P. M. Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck, 173
HOLMBERG, C. *see* HOPPU, K.
HOPPU, K., KOSKIMIES, O., HOLMBERG, C. & HIRVISALO, A. L. Evidence for pre-hepatic metabolism of oral cyclosporine in children, 477
HORSMANS, Y. *see* TINEL, M.
HORTON, R. *see* HUCKER, R. S.
HOUIN, G. *see* DAWES, J.
HOUIN, G. *see* SABATINI, U.
HOUSTON, T. *see* LADLOW, M.
HOWARTH, S. J. *see* MILLSON, D. S.
HOWDEN, C. *see* MILLIGAN, P.
HOWIE, C. A. *see* GEMMILL, J. D.
HOWIE, C. A. *see* MACPHEE, G. J. A.
HOWIE, C. A. *see* SCHAFERS, R. F.
HUCKER, R. S., DAVIES, B. E., PEPPIATT, J. E., QUINLAN, D., HORTON, R., MCCABE, C. A., PRINCE, W. T. & ARNOLD, B. D. C. The pharmacokinetics and tolerance of the penem β-lactamase inhibitor BRL 42715 and cephalzolin following intravenous

administration alone and in combination, 655P
HUDSON, J. E. *see* PARK, Y. H.
HUMMEL, T., FRIEDMANN, T., PAULI, E., NIEBCH, G., BORBE, H. O. & KOBAL, G. Dose-related analgesic effects of flupirtine, 69
HUSSAIN, F. *see* PIRMOHAMED, M.
HVID-JACOBSEN, K. *see* KELBAEK, H.

ILETT, K. F. *see* LEBEDEVS, T. H.
IMPENS, N. *see* DUPONT, A. G.
IND, P. W. *see* IREDALE, M. J.
IREDALE, M. J., DIXON, C. M. S. & IND, P. W. Salbutamol inhibits metabisulphite-induced bronchoconstriction, 637
IRSHAID, Y. M., AL-HADIDI, H. F., ABUIRJEIE, M. A. & RAWASHDEH, N. M. *N*-acetylation phenotyping using dapsone in a Jordanian population, 289
ISAH, A. O., RAWLINS, M. D. & BATEMAN, D. N. Clinical pharmacology of prochlorperazine in healthy young males, 677
ISHIZAKI, T. *see* SOHN, D.-R.

JACKSON, S. H. D. *see* YU, G.
JACQZ-AIGRAIN, E. *see* MURA, C.
JAMES, I. *see* SCIBERRAS, D. G.
JAMES, I. *see* TAYLOR, I. W.
JAMES, M. A. & JONES, J. V. Anti-arrhythmic properties of the α-adrenoceptor blocking drug indoramin, 375
JAMES, O. *see* HERD, B.
JAMIESON, M. *see* WEBSTER, J.
JAY, R. H., STURLEY, R. H., STIRLING, C., MCGARRIGLE, H. H. G., KATZ, M., RECKLESS, J. P. D. & BETTERIDGE, D. J. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia, 417
JEDEMA, J. N. *see* OOSTERHUIS, B.
JEFFERS, T. A. *see* WEBSTER, J.
JOHN, V. A. *see* WILDING, I. R.
JOHNSTON, A. *see* LAWSON, M.
JOHNSTON, A. *see* SALAS-HERRARA, I. G.
JOHNSTON, G. D. *see* BRENNAN, G. M.
JONES, A. K. P. *see* CUNNINGHAM, V. J.
JONES, J. V. *see* JAMES, M. A.
JONES, R. W. *see* ELLMERS, S. E.
JONES, T. *see* CUNNINGHAM, V. J.
JONKMAN, J. H. G. *see* OOSTERHUIS, B.
JORDAN, C. C. *see* MILLSON, D.
JORDAN, C. C. *see* SOHAIL, S.
JORDAN, S. *see* SCIBERRAS, D. G.

KALSO, E. *see* PYHIA, R.
KAMALI, F. *see* FERNER, R. E.
KAMALI, F. & EDWARDS, C. Effect of pirenzepine on gastric emptying and salivary flow, 666P
KAMALI, F., EDWARDS, C. & RAWLINS, M. D. Lack of effect of flosequinan on the pharmacokinetics of theophylline, 124
KARBWANG, J. *see* NA BANGCHANG, K.
KARBWANG, J., WARD, S. A., MILTON, K. A., NA BANGCHANG, K. & EDWARDS, G. Letter to the Editor: Pharmacokinetics of halofantrine in healthy Thai volunteers, 639
KASTRISSIOS, H., TRIGGS, E. J., MOGG, G. A. G. & HIGBIE, J. W. The disposition of bupivacaine following a 72 h interpleural infusion in cholecystectomy patients, 251
KATZ, M. *see* JAY, R. H.
KAYE, C. M. *see* BEERAHEE, A.
KEERY, R. J. *see* THOMAS, M.
KELBAEK, H., MARVING, J., HVID-JACOBSEN, K. & LEVIN, S. Effects of atropine on left ventricular volumes and ejection and filling rates at rest and during exercise, 585
KELMAN, A. *see* MCGOVERN, E. M.
KELMAN, A. *see* MILLIGAN, P.
KELMAN, A. W. *see* GEMMILL, J. D.
KENSETT, M. J. *see* CUNNINGHAM, V. J.
KHAN, A., LANGLEY, S. J., MULLINS, F. G. P., DIXON, J. S. & TOON, S. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine, 519
KIVIST, K. T. *see* NEUVONEN, P. J.
KJEKSHUS, J. *see* GULLESTAD, L.
KLÜPPEL, M. *see* MICHEL, M. C.
KOBAL, G. *see* HUMMEL, T.
KOENE, F. M. M. *see* VAN BAAK, M. A.
KOSKIMIES, O. *see* HOPPU, K.
KRISNAMOORTHY, R. *see* MURA, C.
KUBIK, M. M. *see* WAITE, M. A.
KUGI, A. *see* STACHER, G.
KUMAR, S. *see* PULLAR, T.
KUSAKA, M. *see* SOHN, D.-R.

LACEY, L. F. *see* SCOTT, A. K.
LACOURCIERE, Y., POIRIER, L., PROVENCHER, P. & GUIVARC'H, P. H. Once *vs* twice daily administration of a fixed combination of captopril plus hydrochlorothiazide in essential hypertension: a double-blind crossover study in known responders to a standard combination, 115
LADLOW, M., LANG, C. C., HOUSTON, T., MACRAE, W. & MCDEVITT, D. G. Management of pain caused by cancer: a general practitioner survey, 665P
LADONA, M. G., LINDSTRÖM, B., THYR, C., DUN-REN, P. & RANE, A. Differential foetal development of the *O*- and *N*-demethylation of codeine and dextromethorphan in man, 295
LAINE, K. *see* NEUVONEN, P. J.
LANE, D. A. *see* DAWES, J.
LANG, C. C. *see* LADLOW, M.
LANG, C. C., RAHMAN, A. R. A. & STRUTHERS, A. D. Atrial natriuretic factor inhibits metoclopramide stimulated aldosterone release in man, 51
LANGLEY, S. J. *see* KHAN, A.
LARREY, D. *see* TINEL, M.
LARSEN, S. *see* GULLESTAD, L.
LAWSON, M. *see* SALAS-HERRARA, I. G.
LAWSON, M., FREDERICKS, S. & JOHNSTON, A. The Hawksley random zero sphygmomanometer: unbiased assessment of blood pressure in clinical trials?, 647P
LEAL, M. *see* WILDING, I. R.
LEBEDEVS, T. H., WOJNAR-HORTON, R. E., YAPP, P., ROBERTS, M. J., DUSCI, L. J., HACKETT, L. P. & ILETT, K. F. Excretion of indomethacin in breast milk, 751
LEE, P. S. *see* WAITE, M. A.
LEE, S. *see* WALLEY, T.
LEES, K. R. *see* MACFADYEN, R. J.
LEMMER, B. & NOLD, G. Circadian changes in estimated hepatic blood flow in healthy volunteers, 627
LENNARD, L., HALE, J. P., LILLEYMAN, J. S. & LENNARD, M. S. 6-mercaptopurine metabolism and hypoxanthine phosphoryltransferase activity in childhood leukaemia, 660P
LENNARD, M. S. *see* CREWE, H. K.
LENNARD, M. S. *see* LENNARD, L.
LETTERON, P. *see* TINEL, M.
LETTIS, S. *see* MILLSON, D.
LETTIS, S. *see* SOHAIL, S.
LEVIN, S. *see* KELBAEK, H.
LEVIN, S. L. Letter to the Editors: Salivatory effects induced by selective and non-selective cholinolytics in the chronically denervated human parotid gland, 259
LHERMITTE, M. *see* BROLY, F.
LIBARDONI, M., PIOVAN, D., BUSATO, E. & PADRINI, R. Letter to the Editors: Transfer of propafenone and 5-OH-propafenone to foetal plasma and maternal milk, 527
LIBERSA, C. *see* BROLY, F.
LILLEYMAN, J. S. *see* LENNARD, L.
LINDSTRÖM, B., *see* LADONA, M. G.
LINDUP, W. E. *see* HOLDING, J. D.
LIPWORTH, B. J. *see* NEWNHAM, D. M.
LLOYD, P. *see* WILDING, I. R.
LOUIS, W. J. *see* MCNEIL, J. J.
LUMLEY, P. *see* THOMAS, M.
LUTHRA, S. K. *see* CUNNINGHAM, V. J.

MACDONALD, F. C. *see* WEBSTER, J.
MACFADYEN, R. J., BAINBRIDGE, A. D., LEES, K. R. & REID, J. L. The response to the first dose of an angiotensin converting enzyme inhibitor in uncomplicated hypertension—A placebo controlled study utilising ambulatory blood pressure recording, 393
MACFADYEN, R. J., ELLIOTT, H. L., MEREDITH, P. A. & REID, J. L. Haemodynamic and hormonal responses to low dose ACE inhibitor therapy in salt deplete normotensive male volunteers, 644P
MACFADYEN, R. J., LEES, K. R., GEMMILL, J. D., HILLIS, W. S. & REID, J. L. Transpulmonary pharmacokinetics of an ACE inhibitor (perindoprilat) in man, 193
MACKAY, I. G. *see* TAVERNER, D.
MACKLIN, B. *see* WALLER, D. G.
MACPHEE, G. J. A., HOWIE, C. A., MEREDITH, P. A. & ELLIOTT, H. L. The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol, 591
MACRAE, W. *see* LADLOW, M.
MÄENPÄÄ, H., HEINONEN, O. P. & MANNINEN, V. Medication compliance and serum lipid changes in the Helsinki Heart Study, 409
MAGNA, L. A. *see* CONDINO-NETO, A.
MAHIDA, Y. R. *see* HAWTHORNE, A. B.
MALLETT, C. D. *see* PAGE, K. M.
MANI, V. *see* RILEY, S. A.
MANNI, R. *see* TARTARA, A.
MANNINEN, V. *see* MÄENPÄÄ, H.
MANSOR, S. M., MOLYNEUX, M. E., TAYLOR, T. E., WARD, S. A., WIRIMA, J. J. & EDWARDS, G. Effect of *Plasmodium falciparum* malaria infection on the plasma concentration of α_1-acid glycoprotein and the binding of quinine in Malawian children, 317
MARC-VERGNES, J. P. *see* SABATINI, U.
MARGOLSKEE, D. J. *see* DUPONT, A. G.
MARSHALL, R. W. *see* MERCER, A. J.
MARVING, J. *see* KELBAEK, H.
MASKARY, V. *see* YU, G.
MASSEY, I. *see* SHAH, J.
MASSON, G. *see* BLIN, O.
MCAUSLANE, J. A. N. *see* FREESTONE, S.
MCCABE, C. A. *see* HUCKER, R. S.
MCDERMOTT, B. J. *see* BRENNAN, G. M.
MCDEVITT, D. G. *see* LADLOW, M.
MCDEVITT, D. G. *see* NEWNHAM, D. M.
MCDEVITT, D. G. The effects of frusemide and triamterene on the hypokalaemic and electrocardiographic responses to inhaled terbutaline, 630
MCDEVITT, D. G., CURRIE, D., NICHOLSON, A. N., WRIGHT, N. A. & ZETLEIN, M. B. Central effects of the calcium antagonist, nifedipine, 541
MCEWEN, J. *see* AL-LANQAWI
MCEWEN, J. *see* DAWES, J.
MCFARLANE, N. *see* MCMURRAY, J.
MCGARRIGLE, H. H. G. *see* JAY, R. H.
MCGILL, P. *see* MILLIGAN, P.
MCGOVERN, E. M., THOMSON, A. H., KELMAN, A. & CHAN-LAM, J. M. D. Gentamicin pharmacokinetics in patients with malignant haematologic disease, 649P
MCKAY, G. *see* ALFORD, C.
MCKEAN, H. E. *see* BRITTO, M. R.
MCKEE, P. J., BLACKLAW, J., GILLHAM, R. A. & BRODIE, M. J. The effect of adjuvant sodium valproate on carbamazepine pharmacokinetics in epileptic patients, 653P
MCKEE, P. J. W., BLACKLAW, J., BUTLER, E., GILLHAM, R. A. & BRODIE, M. J. Monotherapy with conventional and controlled release carbamazepine: a double-blind, double-dummy comparison in epileptic patients, 99
MCKILLOP, U. H. *see* YOUNG, J. S.
MCLAREN, M. *see* DAWES, J.
MCMURRAY, J. *see* CLAPPERTON, M.
MCMURRAY, J., GALLOWAY, S., MCFARLANE, N., HENDERSON, E., CHRISTIE, J. & DARGIE, H. J. Catecholamines cause objective and subjective increases in ventilation in humans: a possible mechanism of dyspnoea?, 647P
MCMURRAY, J. *see* GRANT, S.
MCNALLY, C. *see* ELLIOTT, H. L.
MCNEIL, J. J., DRUMMER, O. H., RAYMOND, K., CONWAY, E. L. & LOUIS, W. J. Letter to the Editors: The influence of food on the oral bioavailability of terazosin, 775
MCVEIGH, G. E. *see* BRENNAN, G. M.
MEAD, E. A. *see* BEERAHEE, A.
MEINEKE, I. *see* DE MEY, C.
MEISEL, P. *see* SIEGMUND, W.
MERCER, A. J., MARSHALL, R. W. & RICHENS, A. The effects of a range of doses of ethanol on the acceleration phase duration to deceleration phase duration ratio and peak velocity of saccadic eye movements, 666P
MEREDITH, P. A. *see* ELLIOTT, H. L.
MEREDITH, P. A. *see* GEMMILL, J. D.
MEREDITH, P. A. *see* HARRIGAN, J. R.
MEREDITH, P. A. *see* MACFADYEN, R. J.
MEREDITH, P. A. *see* MACPHEE, G. J. A.
MEREDITH, P. A. *see* SCHAFERS, R. F.
MESTRE, D. *see* BLIN, O.
MEYER, E. C. *see* SOMMERS, DE K.
MICHEL, M. C., KLÜPPEL, M., PHILIPP, T. & BRODDE, O.-E. Does treatment with β-adrenoceptor antagonists *in vivo* alter human adenylate cyclase responsiveness *in vitro*?, 105
MILLER, M. *see* EDWARDS, B. D.
MILLER, S. H. K. *see* SCHAFERS, R. F.
MILLIGAN, P., HOWDEN, C., KELMAN, A., MCGILL, P. & WHITING, B. The consequences of histamine H_2-receptor administration in patients with joint disorders receiving chronic piroxicam therapy, 667P
MILLSON, D. *see* SOHAIL, S.
MILLSON, D., SOHAIL, S., LETTIS, S., MORRIS, S. & JORDAN, C. C. GR68755, a novel, specific 5-HT_3 receptor antagonist: effect on the flare response to intradermal 5-HT in man, 651P
MILLSON, D. S. *see* ANDREW, P. D.
MILLSON, D. S. *see* BRADBURY, A.
MILLSON, D. S., HOWARTH, S. J., RUSHTON, A., WILKINSON, D., HOBSON, S. & HARRY, J. The effects of a 5-HT_2 receptor antagonist (ICI 169,369) on changes in waking EEG, pupillary responses and state of arousal in human volunteers, 447
MILTON, K. A. *see* KARBWANG, J.
MINERS, J. O. *see* BIRKETT, D. J.
MINERS, J. O. *see* OSBORNE, N. J.
MOGG, G. A. G. *see* KASTRISSIOS, H.
MOLONY, B. *see* SHAH, J.
MOLUNTO, P. *see* SILAMUT, K.
MOLYNEUX, M. E. *see* MANSOR, S. M.
MONCRIEFF, J. *see* SOMMERS, DE K.
MONTASTRUC, J. L. *see* SABATINI, U.
MORAES, M. E. A., ARONSSON, J. K. & GRAHAME-SMITH, D. G. The effect of nifedipine on the disposition of strontium gluconate used as a kinetic marker for calcium in healthy volunteers, 441
MORELAND, T. A. *see* AL-LANQAWI
MORICE, A. Good clinical practice and the clinical pharmacologist, 529
MORRIS, S. *see* MILLSON, D.
MORRISON, J. F. J. *see* TEALE, C.
MORSELLI, P. L. *see* FILLASTRE, J. P.
MORTON, J. J. *see* MOTWANI, J. G.
MORTON, J. J. *see* NORTHRIDGE, D. B.
MOTWANI, J. G., FENWICK, M. K. &

STRUTHERS, A. D. Comparison of radioisotope and chemical clearance methods of assessing renal haemodynamics in chronic heart failure, 667P
MOTWANI, J. G., FENWICK, M. K., MORTON, J. J. & STRUTHERS, A. D. Frusemide-induced natriuresis is augmented by ultra-low dose captopril but not by standard doses of captopril in chronic heart failure, 644P
MOVIN-OSSWALD, G. & HAMMARLUND-UDENAES, M. Remoxipride: pharmacokinetics and effect on plasma prolactin, 355
MÜCK, W. *see* TARTARA, A.
MUIR, A. L. *see* DEARY, I. J.
MULLINS, F. G. P. *see* KHAN, A.
MURA, C., BROYARD, J. P., JACQZ-AIGRAIN, E. & KRISNAMOORTHY, R. Letter to the Editors: Distinct phenotypes and genotypes of debrisoquine hydroxylation among Europeans and Chinese, 135
MURKITT, G. S. *see* ANDREW, P. D.
MURRAY, G. R. *see* AHMED, J. H.
MURRAY, G. R. *see* WEBSTER, J.
MUSTOFA, M., SURYAWATI, S., DWIPRAHASTO, I. & SANTOSO, B. The relative bioavailability of diclofenac with respect to time of administration, 246
MYERS, A. *see* WAITE, M. A.

NA BANGCHANG, K. *see* KARBWANG, J.
NA BANGCHANG, K., KARBWANG, J., BUNNAG, D., HARINASUTA, T. & BACK, D. J. Letter to the Editors: The effect of metoclopramide on mefloquine pharmacokinetics, 640
NALINE, E., SANCEAUME, M., TOTY, L., BAKDACH, H., PAYS, M. & ADVENIER, C. Penetration of minocycline into lung tissues, 402
NEUVONEN, P. J. & KIVIST, K. T. The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations, 215
NEUVONEN, P. J., ROIVAS, L., LAINE, K. & SUNDHOLM, O. The bioavailability of sustained release nicotinic acid formulations, 473
NEWNHAM, D. M., MCDEVITT, D. G. & LIPWORTH, B. J. The effects of frusemide and triamterene on the hypokalaemic and electrocardiographic responses to inhaled terbutaline, 630
NG, H. W. K., WALLEY, T., TSAO, Y. & BRECKENRIDGE, A. M. Comparison and reproducibility of transthoracic electrical bioimpedance (TEB) and dual beam Doppler ultrasound measurement of cardiac output in normal subjects, 646P
NG, H. W. K., WALLEY, T., TSAO, Y. & BRECKENRIDGE, A. M. Comparison of reproducibility of transthoracic bioimpedance and dual beam Doppler ultrasound measurement of cardiac function in healthy volunteers, 275
NICHOLLS, D. P. *see* YOUNG, J. S.
NICHOLS, D. J., BYE, A. & NOVAK, E. Pharmacokinetics of trospectomycin sulphate in healthy subjects after single intravenous and intramuscular dose, 255
NICHOLSON, A. N. *see* MCDEVITT, D. G.
NIEBCH, G. *see* HUMMEL, T.
NIOPAS, J., TOON, S. & ROWLAND, M. Further insight into the stereoselective interaction between warfarin and cimetidine in man, 508
NOLD, G. *see* LEMMER, B.
NORDBY, G. *see* GULLESTAD, L.
NORTHRIDGE, D. B. Effects of candoxatril, a novel endopeptidase inhibitor, compared with frusemide in mild chronic heart failure, 645P
NORTHRIDGE, D. B., MORTON, J. J., HENDERSON, E. & DARGIE, H. J. Are the beneficial effects of converting enzyme inhibition in chronic heart failure due to neuroendocrine suppression?, 661P
NOTARIANNI, L. J. *see* ELLMERS, S. E.
NOTARIANNI, L. J. *see* OLIVER, S. E.
NOVAK, E. *see* NICHOLS, D. J.

O'GRADY, J. *see* VANE, J.
OGG, G. D. *see* AL-LANQAWI
OLIVER, S. E., FARMER, K. C., SPIGELMAN, A., PHILIPS, R. K., BENNETT, P. N. & NOTARIANNI, L. J. Acetylation status in familial polyposis and colorectal carcinoma, 650P
OLKKOLA, K. T. *see* PYHIA, R.
OOSTERHUIS, B., JONKMAN, J. H. G., ANDERSSON, T., ZUIDERWIJK, P. B. M. & JEDEMA, J. N. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose, 569
OSBORNE, N. J., TONKIN, A. L. & MINERS, J. O. Interethnic differences in drug glucuronidation: a comparison of paracetamol metabolism in Caucasians and Chinese, 765
PADRINI, R. *see* LIBARDONI, M.
PAGE, B. C. *see* CUNNINGHAM, V. J.
PAGE, K. M., MALLETT, C. D. & FACCHINI, V. Pharmacokinetics of 2-*n*-octadecyl indole-5-carboxylic acid, after repeat dosing to man, 655P
PALMER, J. L. *see* ANDREW, P. D.
PARIETTI, L. *see* TARTARA, A.
PARK, B. K. *see* BARNARD, S.
PARK, B. K. *see* PIRMOHAMED, M.
PARK, B. K. *see* TINGLE, M. D.
PARK, C.-W. *see* SOHN, D.-R.
PARK, Y. H., HUDSON, J. E., BARKER, R. C., YORK, B. M. & BRAZZELL, R. K. Metabolism of the aldose reductase inhibitor ALØ1567 in man, 221
PARKER, L. R. *see* ELLMERS, S. E.
PATEL, M. *see* ENDRENYI, L.
PAULI, E. *see* HUMMEL, T.
PAYS, M. *see* NALINE, E.
PAYS, M. *see* SPREUX-VAROQUAUX, O.
PEAKER, S. *see* PULLAR, T.
PEARSON, S. B. *see* TEALE, C.
PENNA, A. & BUCHANAN, N. Paracetamol poisoning in children and hepatotoxicity, 143
PEPPIATT, J. E. *see* HUCKER, R. S.
PÉRÉ, J. C. *see* TUBERET, P.
PERUCCA, E. *see* TARTARA, A.
PESSAYRE, D. *see* TINEL, M.
PETRIE, J. C. *see* WEBSTER, J.
PHILIPP, T. *see* MICHEL, M. C.
PHILIPS, R. K. *see* OLIVER, S. E.
PHILLIPS, S. C. *see* GRAY, S. J.
PHILLIPS, S. C., ROLAN, P. E., GRAY, S. J. & POSNER, J. Effect of i.v. infusion of a novel enkephalin analogue (443C81) on metabisulphite-induced bronchoconstriction and intradermal histamine flare in healthy volunteers, 664P
PIERCE, D. M. *see* FOWLES, S. E.
PIERCE, D. M. *see* PRATT, S. K.
PIKE, V. W. *see* CUNNINGHAM, V. J.
PIOVAN, D. *see* LIBARDONI, M.
PIRMOHAMED, M., COLEMAN, M. D., HUSSAIN, F., BRECKENRIDGE, A. M. & PARK, B. K. Direct and metabolism dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes, 303
PIRMOHAMED, M., GRAHAM, A., ROBERTS, P., SMITH, D., CHADWICK, D., BRECKENRIDGE, A. M. & PARK, B. K. Carbamazepine-hypersensitivity: assessment of clinical and *in vitro* cross-reactivity with phenytoin and oxcarbazepine, 741
POIRIER, L. *see* LACOURCIERE, Y.
PORQUET, C. *see* FILLASTRE, J. P.
POSNER, J. Clinical

pharmacology—mutual benefits from greater collaboration between academia and the pharmaceutical industry, 531
POSNER, J. *see* CHOUDRY, N. B.
POSNER, J. *see* GRAY, S. J.
POSNER, J. *see* PHILLIPS, S. C.
POSNER, J., WEBSTER, H. & YUEN, W. C. Investigation of the ability of lamotrigine, a novel antiepileptic drug, to induce mixed function oxygenase enzymes, 658P
POSTON, L. *see* WOOLFSON, R. G.
POWELL, M. L. *see* WILDING, I. R.
POZET, N. *see* FERRY, N.
PRATI, P. L. *see* CARBONI, G. P.
PRATT, S. K., FOWLES, S. E., PIERCE, D. M. & PRINCE, W. T. An investigation of the potential interaction between cimetidine and famciclovir in non-patient volunteers, 657P
PRESCOTT, L. F. *see* FREESTONE, S.
PRINCE, W. T. *see* FOWLES, S. E.
PRINCE, W. T. *see* HUCKER, R. S.
PRINCE, W. T. *see* PRATT, S. K.
PROVENCHER, P. *see* LACOURCIERE, Y.
PRZEPIORKA, D. *see* SCHWINGHAMMER, T. L.
PULLAR, T. Compliance with drug therapy, 535
PULLAR, T., KUMAR, S., CHRYSTYN, H., RICE, P., PEAKER, S. & FEELY, M. The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance, 329
PYHIA, R., OLKKOLA, K. T., SEPPÄLÄ, T. & KALSO, E. The pharmacokinetics of oxycodone after intravenous injection in adults, 516

QUINLAN, D. *see* HUCKER, R. S.

RAHMAN, A. R. A. *see* LANG, C. C.
RANE, A. *see* LADONA, M. G.
RASCOL, A. *see* SABATINI, U.
RASMUSSEN, H. S. *see* GEMMILL, J. D.
RAWASHDEH, N. M. *see* IRSHAID, Y. M.
RAWLINS, M. D. *see* FERNER, R. E.
RAWLINS, M. D. *see* ISAH, A. O.
RAWLINS, M. D. *see* KAMALI, F.
RAYMOND, K. *see* MCNEIL, J. J.
RECKLESS, J. P. D. *see* JAY, R. H.
REID, J. L. *see* ELLIOTT, H. L.
REID, J. L. *see* MACFADYEN, R. J.
REID, J. L. *see* SCHAFERS, R. F.
RELLING, M. V. *see* TURGEON, J.
RENWICK, A. G. *see* WALLER, D. G.
RIBEIRO, J. D. *see* CONDINO-NETO, A.
RICE, P. *see* PULLAR, T.
RICHARDSON, P. D. I. *see* WAITE, M. A.
RICHENS, A. *see* MERCER, A. J.
RILEY, S. A., TAVARES, I. A., BISHAI, P. M., BENNETT, A. & MANI, V. Mesalazine release from coated tablets: effect of dietary fibre, 248
RIMOY, G. H., BHASKAR, N. K., WRIGHT, D. M. & RUBIN, P. C. Mechanism of diuretic action of spiradoline (U-62066E) —a kappa opioid receptor agonist in the human, 611
RIMOY, G. H. *see* WRIGHT, D. M.
RITTER, J. M. *see* BARROW, S. E.
RITTER, J. M. *see* BENJAMIN, M.
RITTER, J. M. *see* WOOLFSON, R. G.
ROBERTS, M. J. *see* LEBEDEVS, T. H.
ROBERTS, P. *see* PIRMOHAMED, M.
ROBERTSON, C. S. *see* WILDING, I. R.
ROBERTSON, R. P. *see* DIEM, P.
RODEN, D. M. *see* TURGEON, J.
RODGER, R. S. C. *see* AHMED, J. H.
ROIVAS, L. *see* NEUVONEN, P. J.
ROLAN, P. E. *see* GRAY, S. J.
ROLAN, P. E. *see* PHILLIPS, S. C.
ROSENFELD, C. S. *see* SCHWINGHAMMER, T. L.
ROSENZWEIG, P. *see* FILLLASTRE, J. P.
ROSEVEARE, C. *see* WALLER, D. G.
ROWLAND, M. *see* NIOPAS, J.
ROY-CHAUDURY, P. *see* WEBSTER, J.
RUBIN, P. C. *see* RIMOY, G. H.
RUBIN, P. C. *see* WRIGHT, D. M.
RUSHTON, A. *see* MILLSON, D. S.
RUTTER, N. *see* BARRETT, D. A.
RYMER, J. *see* BENJAMIN, M.

SABATINI, U., RASCOL, O., CELSIS, P., HOUIN, G., RASCOL, A., MARC-VERGNES, J. P. & MONTASTRUC, J. L. Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms, 229
SALAS-HERRARA, I. G., LAWSON, M., JOHNSTON, A., TURNER, P., GOTT, D. M. & DENNIS, M. J. Plasma metronidazole concentrations after single and repeated vaginal pessary administration, 621
SANCEAUME, M. *see* NALINE, E.
SANTOSO, B. *see* MUSTOFA, M.
SASSARD, J. *see* FERRY, N.
SCARDOVI, A. B. *see* CARBONI, G. P.
SCHAFERS, R. F., ELLIOTT, H. L., HOWIE, C. A. & REID, J. L. Studies with abanoquil (UK-52,046) a novel quinolone α_1-adrenoceptor antagonist: I. Effects of blood pressure, heart rate and pressor responsiveness in normotensive subjects, 599
SCHAFERS, R. F., ELLIOTT, H. L., MEREDITH, P. A., MILLER S. H. K. & REID, J. L. Studies with abanoquil (UK-52,046) a novel quinolone α_1-adrenoceptor antagonist: II. Duration of action, pharmacokinetics and concentration-effect relationships in normotensive subjects, 605
SCHNEIDER, C. *see* STACHER, G.
SCHOORS, D. F. *see* DUPONT, A. G.
SCHWARTZ, J. I. *see* DUPONT, A. G.
SCHWINGHAMMER, T. L., PRZEPIORKA, D., VENKATARAMANAN, R., WANG, C. P., BURCKART, G. J., ROSENFELD, C. S. & SHADDUCK, R. K. The kinetics of cyclosporine and its metabolites in bone marrow transplant patients, 323
SCIBERRAS, D. G., JORDAN, S., GILL, D., BABER, N. S. & JAMES, I. The role of histamine in the acute inflammatory responses to intravenous platelet activating factor, 85
SCOTT, A. K. WALLEY, T., BRECKENRIDGE, A. M., LACEY, L. F. & FOWLER, P. A. Lack of an interaction between propranolol and sumatriptan, 581
SCULLY, N. L. *see* THOMAS, M.
SENN, S. J. Letter to the Editors: Problems with the two stage analysis of crossover trials, 133
SEPPÄLÄ, T. *see* PYHIA, R.
SERRATRICE, G. *see* BLIN, O.
SHADDUCK, R. K. *see* SCHWINGHAMMER, T. L.
SHAH, J., TEITELBAUM, P., MOLONY, B., GABUZDA, T. & MASSEY, I. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects, 761
SHANKS, R. G. *see* FOX, J. S.
SHAW, P. N. *see* BARRETT, D. A.
SHAWKET, S., DICKERSON, C., HAZLEMAN, B. & BROWN, M. J. Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin, 209
SHEDLOFSKY, S. I. *see* SMITH, D. A.
SHIN, S.-G. *see* SOHN, D.-R.
SIEGMUND, W., FENGLER, J. D., FRANKE, G., ZSCHIESCHE, M., EIKE, O., MEISEL, P., WALKOW, R. & EIKE, *N*-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome, 467
SILAMUT, K., MOLUNTO, P., HO, M., DAVIES, T. M. E. & WHITE, N. J. α_1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria, 311

SIM, S. M., BACK, D. J. & BRECKENRIDGE, A. M. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes, 17
SIODLAK, M. Z. *see* HOLDING, J. D.
SKJELBO, E. *see* BRØSEN, K.
SMITH, D. *see* PIRMOHAMED, M.
SMITH, D. A., CHANDLER, M. H. H., SHEDLOFSKY, S. I., WEDLUND, P. J. & BLOUIN, R. A. Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin, 735
SMITH, S. E. *see* THOMAS, S. H. L.
SNYMAN, J. R. & SOMMERS, DE K. Effect of enalapril on allergen-induced cutaneous hypersensitivity reaction, 713
SOHAIL, S., LETTIS, S., MILLSON, D. & JORDAN, C. C. Comparison of an auto-injector device with conventional intradermal injection of 5-HT to produce a flare response in man, 663P
SOHAIL, S. *see* MILLSON, D.
SOHN, D.-R. SHIN, S.-G., PARK, C.-W., KUSAKA, M. CHIBA, K. & ISHIZAKI, T. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations, 504
SOMMERS, DE K. *see* SNYMAN, J. R.
SOMMERS, DE K., MEYER, E. C. & MONCRIEFF, J. The influence of co-administered organic acids on the kinetics and dynamics of frusemide, 489
SOONS, P. A. & BREIMER, D. D. Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects, 11
SOONS, P. A., DE BOER, A., COHEN, A. F. & BREIMER, D. D. Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green, 697
SPIERDIJK, JOH. *see* VEERING, B. Th.
SPIGELMAN, A. *see* OLIVER, S. E.
SPREUX-VAROQUAUX, O., DOLL, J., DUTOT, C., GRANDJEAN, N., CORDONNIER, P., PAYS, M., ANDRIEU, J. & ADVENIER, C. Pharmacokinetics of molsidomine and its active metabolite, linsidomine, in patients with liver cirrhosis, 399
STACHER, G., BERGMANN, H., GRANSER-VACARIU, G. V., WIENAGROTZKI, S., WENZEL-ABATZI, Th.-A., GAUPMANN, G., KUGI, A., STEINRINGER, H., SCHNEIDER, C. & HOBART, J. Lack of systematic effects of the 5-hydroxytryptamine$_3$ receptor antagonist ICS 205-930 on gastric emptying and antral motor activity in patients with primary anorexia nervosa, 685
STANFORD, C. F. *see* YOUNG, J. S.
STEINRINGER, H. *see* STACHER, G.
STELL, P. M. *see* HOLDING, J. D.
STEVENSON, I. H. *see* AL-LANQAWI
STIEKEMA, J. C. J. *see* DE BOER, A.
STIRLING, C. *see* JAY, R. H.
STORR, R. C. *see* BARNARD, S.
STRATTON, P. D. *see* BARROW, S. E.
STRUTHERS, A. D. *see* LANG, C. C.
STRUTHERS, A. D. *see* MOTWANI, J. G.
STURLEY, R. H. *see* JAY, R. H.
SUNDBERG, S. & GORDIN, A. COMT inhibition with nitecapone does not affect the tyramine pressor response, 130
SUNDHOLM, O. *see* NEUVONEN, P. J.
SURYAWATI, S. *see* MUSTOFA, M.
SWIFT, C. G. *see* YU, G.

TAN, E. S. *see* VAN BAAK, M. A.
TARTARA, A., GALIMBERTI, C. A., MANNI, R., PARIETTI, L., ZUCCA, C., BAASCH, H., CARESIA, L., MÜCK, W., BARZAGHI, N., GATTI, G. & PERUCCA, E. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epilepsy, 335
TATTERSFIELD, A. E. *see* WAHEDNA, I.
TAVARES, I. A. *see* RILEY, S. A.
TAVERNER, D., MACKAY, I. G., CRAIG, K. & WATSON, M. L. The effects of selective β-adrenoceptor antagonists and partial agonist activity on renal function during exercise in normal subjects and those with moderate renal impairment, 387
TAYLOR, A. C. *see* BEERAHEE, A.
TAYLOR, I. W., CHASSEAUD, L. F., TAYLOR, T., JAMES, I., DORF, G. & DARRAGH, A. Pharmacokinetics of the anti-inflammatory drug ximoprofen in healthy young and elderly subjects: comparison with elderly rheumatic patients, 242
TAYLOR, T. *see* TAYLOR, I. W.
TAYLOR, T. E. *see* MANSOR, S. M.
TEALE, C. & PEARSON, S. B. Regular nebulised terbutaline in chronic obstructive airways disease: dose-response studies fail to detect tolerance, 111
TEALE, C., MORRISON, J. F. J. & PEARSON, S. B. Effects of H_1-receptor blockade with terfenadine in nocturnal asthma, 371
TEITELBAUM, P. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects, 761
TEITELBAUM, P. *see* SHAH, J.
THOM, M. *see* BENJAMIN, M.
THOMAS, J. R. *see* VERPOOTEN, G. A.
THOMAS, M. *see* ANDREW, P. D.
THOMAS, M. *see* BRADBURY, A.
THOMAS, M., KEERY, R. J., CHARTER, M. K., SCULLY, N. L., CHILTON, J. E. & LUMLEY, P. The pharmacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjects, 181
THOMAS, S. H. L., CLARK, K. L., ALLEN, R. & SMITH, S. E. A comparison of the cardiovascular effects of phenylpropanolamine and phenylephrine containing proprietary cold remedies, 705
THOMSON, A. H. *see* MCGOVERN, E. M.
THYR, C. *see* LADONA, M. G.
TIMERICK, S. J. B. *see* WAITE, M. A.
TINEL, M., BERSON, A., PESSAYRE, D., LETTERON, P., CATTONI, M. P., HORSMANS, Y. & LARREY, D. Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population, 729
TINGLE, M. D., COLEMAN, M. D. & PARK, B. K. The effect of preincubation with cimetidine on the *N*-hydroxylation of dapsone by human liver microsomes, 120
TIPLADY, B. Development of a test battery for the measurement of changes in psychological performance, 669P
TIPLADY, B. *see* YU, G.
TJIA, J. F. *see* BACK, D. J.
TODD, S. D. *see* BENJAMIN, M.
TODD, S. D. *see* WOOLFSON, R. G.
TONKIN, A. L. *see* OSBORNE, N. J.
TOON, S. *see* KHAN, A.
TOON, S. *see* NIOPAS, J.
TOTY, L. *see* NALINE, E.
TREGASKIS, B. *see* AL-LANQAWI
TRIGGS, E. J. *see* KASTRISSIOS, H.
TRIMBLE, E. R. *see* YOUNG, J. S.
TSAO, Y. *see* NG, H. W. K.
TUBERET, P., BÉGAUD, B., HARAMBURU, F. & PÉRÉ, J. C. Spontaneous reporting: how many cases are required to trigger a warning?, 407
TUCKER, G. T. *see* CREWE, H. K.
TURGEON, J., EVANS, W. E., RELLING, M. V., WILKINSON, G. R. & RODEN, D. M. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism, 283
TURNER, P. *see* SALAS-HERRARA, I. G.

UNDRE, N. A. *see* BEERAHEE, A.
USMAN, F. *see* WALLER, D. G.

VAN BAAK, M. A., KOENE, F. M. M., VERSTAPPEN, F. T. J. & TAN, E. S. Exercise performance during captopril and atenolol treatment in hypertensive patients, 723
VANDAMME, N. *see* BROLY, F.
VANE, J. & O'GRADY, J. Clinical Pharmacology in the pharmaceutical industry, 155
VEERING, B. Th., BURM, A. G. L., GLADINES, M. P. R. R. & SPIERDIJK, JOH. Age does not influence the serum protein binding of bupivacaine, 501
VENKATARAMANAN, R. *see* SCHWINGHAMMER, T. L.
VERE, D. W. Payments to healthy volunteers—ethical problems, 141
VERE, D. W. *see* BYROM, H.
VERPOOTEN, G. A., GENISSEL, P. M., THOMAS, J. R. & DE BROE, M. E. Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency, 187
VERSTAPPEN, F. T. J. *see* VAN BAAK, M. A.
VILELA, M. M. S. *see* CONDINO-NETO, A.

WAHEDNA, I., WISNIEWSKI, A. S. & TATTERSFIELD, A. E. Effect of RG 12525, an oral leukotriene D_4 antagonist, on the airway response to inhaled leukotriene D_4 in subjects with mild asthma, 512
WAITE, M. A., BONE, M. E., KUBIK, M. M., MYERS, A., DAVEY, N. B., LEE, P. S., BLYCHERT, E., RICHARDSON, P. D. I., TIMERICK, S. J. B. & WATTS, D. A. A comparison of the efficacy and tolerability of felodipine ER and atenolol given as monotherapy in mild to moderate hypertension, 661P
WALKER, S. M. *see* WILDING, I. R.
WALKOW, R. *see* SIEGMUND, W.
WALLER, D. G., ROSEVEARE, C., RENWICK, A. G., MACKLIN, B. & GEORGE, C. F. Gastric emptying in healthy volunteers after multiple doses of levodopa, 691
WALLER, D. G., USMAN, F., RENWICK, A. G., MACKLIN, B. & GEORGE, C. F. Oral amino acids and gastric emptying: an investigation of the mechanism of levodopa-induced gastric stasis, 771
WALLEY, T., LEE, S. & COLEMAN, J. A study of the frequency and crossreactivity of antibodies to benzylpenicillin and other β-lactam antibiotics, 664P
WALLEY, T. *see* NG, H. W. K.
WALLEY, T. *see* SCOTT, A. K.
WANG, C. P. *see* SCHWINGHAMMER, T. L.
WANWIMOLRUK, S. & CHALCROFT, S. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine, 617
WARD, S. A. *see* KARBWANG, J.
WARD, S. A. *see* MANSOR, S. M.
WATSON, M. L. *see* TAVERNER, D.
WATTS, D. A. *see* WAITE, M. A.
WEBB, D. J. *see* HAYNES, W. G.
WEBSTER, H. *see* POSNER, J.
WEBSTER, J., PETRIE, J. C., JEFFERS, T. A., ROY-CHAUDURY, P., CRICHTON, W., WITTE, K., JAMIESON, M., MACDONALD, F. C., BEARD, M., DOW, R. J. & MURRAY, G. R. Nicardipine sustained release in hypertension, 433
WEDLUND, P. J. *see* BRITTO, M. R.
WEDLUND, P. J. *see* SMITH, D. A.
WELLER, C. *see* DOBBS, R. J.
WENZEL-ABATZI, Th.-A. *see* STACHER, G.
WESTON, A. H . *see* EDWARDS, B. D.
WHITE, N. J. *see* SILAMUT, K.
WHITE, V. *see* BYROM, H.
WHITEHEAD, E. M. *see* FOX, J. S.
WHITING, B. *see* MILLIGAN, P.
WIENAGROTZKI, S. *see* STACHER, G.
WILDING, I. R., DAVIS, S. S., HARDY, J. G., ROBERTSON, C. S., JOHN, V. A., POWELL, M. L., LEAL, M., LLOYD, P. & WALKER, S. M. Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine, 573
WILKINSON, D. *see* MILLSON, D. S.
WILKINSON, G. R. *see* TURGEON, J.
WIRIMA, J. J. *see* MANSOR, S. M.
WISNIEWSKI, A. S. *see* WAHEDNA, I.
WITTE, K. *see* WEBSTER, J.
WOJNAR-HORTON, R. E. *see* LEBEDEVS, T. H.
WOODHOUSE, K. *see* HERD, B.
WOODS, F. R. *see* CREWE, H. K.
WOODS, K. L. Possible pharmacological actions of magnesium in acute myocardial infarction, 3
WOOLFSON, R. G., BENJAMIN, N., TODD, S. D., POSTON, L. & RITTER, J. M. Ouabain and responses to endothelium-dependent vasodilators in the human forearm, 758
WRIGHT, D. M. *see* RIMOY, G. H.
WRIGHT, D. M., RIMOY, G. H., BHASKAR, N. K. & RUBIN, P. C. Effect of the κ-selective opioid agonist U-62,066E in man, 652P
WRIGHT, N. A. *see* MCDEVITT, D. G.
WRIGHT, P. *see* HERD, B.
WYNNE, H. *see* HERD, B.

YAPP, P. *see* LEBEDEVS, T. H.
YEULET, S. *see* DE MEY, C.
YORK, B. M. *see* PARK, Y. H.
YOUNG, J. S., GOH, E. M. L., MCKILLOP, U. H., STANFORD, C. F., NICHOLLS, D. P. & TRIMBLE, E. R. Magnesium status and digoxin toxicity, 717
YU, G., MASKARY, V., JACKSON, S. H. D., SWIFT, C. G. & TIPLADY, B. A comparison of the central nervous system effects of caffeine and theophylline in elderly subjects, 341
YUEN, W. C. *see* POSNER, J.

ZETLEIN, M. B. *see* MCDEVITT, D. G.
ZSCHIESCHE, M. *see* SIEGMUND, W.
ZUCCA, C. *see* TARTARA, A.
ZUIDERWIJK, P. B. M. *see* OOSTERHUIS, B.

SUBJECT INDEX

This index was compiled from the keywords

(P = proceedings)

α_1-acid glycoprotein, 317
α_1-adrenoceptor agonist, 599
α_1-adrenoceptor antagonist, 605
α-adrenoceptor blocker, 375
α-adrenoceptor blocking drug, 775
ACE inhibition, 393, 644P, 723
ACE inhibitors, 662P
ALØ1567, 221
Abanoquil, 599, 605
Absorption interactions, 215
Academia, 531
Academic research, 151
Acetylation, 289
Acetylation status, 650P
Adenylate cyclase, 105
Administration time, 246
Adrenocorticotrophin, 51
Adverse drug reactions, 407
Adverse effects, 433
Age, 501, 735, 761
Ageing, 768
Aldose reductase inhibitor, 221
Aldosterone, 51
Allopurinol, 238
Aluminium, 642
Ambulatory blood pressure recording, 393
Amino acids, 771
Analgesimetry, 69
Angiotensin II, 523
Angiotensin-converting enzyme inhibitors, 187
Antagonism, 447
Anti-arrhythmic, 375, 429
Antiarrhythmic drugs, 267
Anticholinesterase activity, 260
Anticoagulant activity, 361
Anticonvulsants, 335
Antihypertensive drug, 134
Antimuscarinic, 260
Antimycotic drugs, 624
Antipyrine, 23
Antithrombotic, 361
Antral motor activity, 685
Apomorphine, 229, 551
Arrhythmia, 375
Aspirin, 77
Assay, 367
Asthma, nocturnal, 371
Atenolol, 39, 201, 347, 387, 662P
Atopic, 85
Atrial fibrillation, 267
Atrial natriuretic factor, 51
Atropine, 585
Attention, 341
Auto-injector device, 663P

β-adrenoceptor, 630
β-adrenoceptor antagonists, 201, 379
β-adrenoceptor blockade, 723
β-lactam antibiotics, 664P
β-lactamase inhibitor, 665P
β_2-microglobulin, 495
BRL 34915, 45
BRL 38227, 656P
BRL 42715, 655P
Benzylpenicillin, 664P
Betahistine, 455
Bimodal distributions, 159
Bioavailability, 246, 473, 477, 658, 775
Biotransformation, 221
Blood pressure, 130, 647P
Body sway, 541
Bone marrow, 323
Bopindolol, 755
Bronchoconstriction, 633, 637
Bupivacaine, 251, 501
Buspirone, 91

COMT inhibition, 130
Caffeine, 341, 705
Calcitonin gene related peptide, 209, 645P
Calcium, 441
Calcium antagonists, 441
Calcium channel blockers, 335
Cancer, 665P
Candoxatril, 645P
Capsaicin, 633
Capsule counting, 409
Captopril, 115, 347, 644P
Carbamazepine, 99, 573, 653P, 741
Cardiac output, 275, 646P
Cardiovascular effects, 45, 705
Catecholamines, 647P
Central nervous system, 69
Cephazolin, 655P
Cerebral blood flow, 229
Children, 143, 317, 477
Cholecystectomy, 251
Cholestyramine, 417
Cholinolytics, 259
Chronic, 187
Chronic heart failure, 644P, 645P, 661P, 667P
Chronic obstructive airways disease, 111
Chronic renal failure, 495
Chronic stable angina pectoris, 755
Ciclopralol, 261
Cimetidine, 120, 260, 508, 519, 656P
Circadian rhythm, 627
Cisplatin, 173
Clinical Pharmacology, 151, 155, 529
Clinical trial, 99
Clinical trials, 141
Clobazam, 91
Codeine, 295
Cognition, 347
Cold remedies, 705
Collaboration, 531
Colorectal carcinoma, 650P
Colour vision, 717
Compliance, 329, 535
Concentration effect analysis, 591
Concentration-response, 238
Continuous infusion, 697
Controlled-release, 99
Converting enzyme inhibition, 661P
Copal UA 251, 433
Cough, 633
Cromakalin, 45
Crossover trial, 1, 133
Cutaneous hypersensitivity reaction, 713
Cyclosporin, 323, 624
Cyclosporin A, 134, 477
Cytochrome P450, 23
Cytochrome P-450IIC, 235
Cytochrome P-450IID6, 235, 283, 295, 659P
Cytochrome P450IIIA, 295
Cytotoxicity, 303

Dapsone, 120, 289
Debrisoquine, 283, 467, 617
Debrisoquine hydroxylation, 135
Debrisoquine/sparteine-type polymorphism, 459
Delayed-release mesalazine, 248
Dermatan sulphate, 361
Dextromethorphan, 295
Diabetes, 563, 648P
Diamorphine, 31
Diclofenac, 246
Diet, 235
Dietary fibre, 248
Digoxin, 63, 409, 569, 650P, 717
Dihydropyridine, 335
Dilevalol, 591
Disposition, 251, 654P
Diuresis, 611
Diuretic efficiency, 489
Domperidone, 229, 483
Dopamine, 483, 551
Doppler, 275
Doppler renal blood flow, 611
Doppler ultrasound, 646P
Dose regimen, 31
Dose-response relationship, 69
Driving, 455
Drug analysis, 323
Drug glucuronidation, 765
Drug interaction, 124, 335
Drug metabolism, 323
Drug oxidation, 459
Drug polymorphism, 159

Drug-drug interaction, 508
Dyspnoea, 647P

EEG, 541
Elderly, 650P
Elderly hypertension, 591
Elderly patients, 242
Electrocardiogram, 630
Electroencephalogram, 69
Enalapril, 645P, 713
Endopeptidase inhibitor, 645P
Endothelium, 648P, 758
Enkephalin analogue, 663P, 664P
Enzyme induction, 23
Epanolol, 387
Epilepsy, 99, 335, 653P, 658P
Essential hypertension, 393
Ethanol, 656P, 666P
Ethics, 141
Ethnic differences, 135
European community, 671
Evoked potential, 69
Exercise, 387, 660P, 723
Exercise test, 755

Faculty of Pharmaceutical Medicine, 265
Famciclovir, 657P, 658P
Familial hypercholesterolaemia, 417
Familial polyposis, 650P
Fatty acids, 423
Felodipine ER, 662P
Fenofibrate, 423
Fentanyl, 668P
First dose hypotension, 393
Flare, 85
Flosequinan, 124
Fluorine, 651P
Fluoxetine, 136
Flupirtine, 69
Foetal plasma 527
Food, 658P, 775
Frusemide, 489, 630, 644P, 645P

GR 68755, 651P, 654P, 668P
Gamma scintigraphy, 573
Gastric emptying, 138, 666P, 685, 691
Gastric stasis, 771
Gastric ulcer, 77
Gemfibrozil, 409
Genetic polymorphism, 459, 617
Genotype, 135, 283
Gentamicin, 649P
Geriatric medicine, 405
Gilbert's syndrome, 467
Glibenclamide, 215
Glomerular filtration rate, 387
Glucagon, 319
Glucuronidation, 17, 768
Glucose, 215
Good clinical practice, 529, 671
Graphical method, 159

Haemodynamic response, 644P
Haemodynamics, 723
Halofantrine, 639
Hawksley random zero sphygmomanometer, 647P
Head and neck cancer, 173
Healthy volunteers, 467
Heart rate, 201
Hepatic blood flow, 697
Hepatotoxicity, 143, 651P
Hexobarbitone, 735
Histamine, 85, 367, 371
Histamine H_2-receptor antagonists, 667P
Home recordings, 433
Homoeopathy, 39
5-HT reuptake inhibitors, 659P
5-HT_2 receptor antagonist, 447
5-HT_3 receptor antagonist, 651P, 654P, 685
Human, 671, 768
Human CNS dynamics, 447
Human foetal liver, 295
Human liver, 624
5-hydroxytryptamine, 663P
Hydrochlorothiazide, 115
Hypercholesterolaemia, 127, 423
Hypertension, 115, 187, 347, 433, 662P, 723
Hypoalbuminaemia, 173
Hypoxanthine, 660P
Hypoxanthine phosphoribosyl-transferase activity, 660P

ICI 118,551, 105
ICI 169,369, 447
ICI-18551, 201
ICS 205-930, 685
Indocyanine green, 193, 697
Indocyanine green kinetics, 627
Indomethacin, 713, 751
Indoramin, 375
Induction, 658P, 735
Infant, 751
Inhibition, 120, 624
Insulin, 215
Interaction, 63, 379, 405, 657P, 667P
Interactions, 23
Interethnic differences, 504, 765
Interpleural infusion, 251
Intradermal injection, 663P
Intravenous infusion, 31
Intrinsic crossover, 573
Inulin clearance, 495
Ispaghula husk, 248

Jordanians, 289

K^+-channel opening properties, 134
κ-selective opioid agonist, 652P
Ketogenesis, 563
Ketotifen, 713
Kidney failure, 187

LDL, 127
Lamotrigine, 658P
Leucocyte migration, 557
Leukaemia, childhood, 660P
Leukotriene D_4-receptor antagonist, 512, 653P
Levodopa, 691, 771
Lipoproteins, 423
Liver blood flow, 627
Liver cirrhosis, 399
Liver microsomes, 17
Lung, 402
Lung inflammation, 557

Magnesium, 3, 717
Magnesium hydroxide, 215
Magnocellular pathway, 551
Malaria, 311
Malaria infection, 317
Man, 355
Medical ethics, 671
Medication compliance, 409
Mefloquine, 641
6-mercaptopurine, 660P
Metabolism, 120, 477, 617
Methaemoglobinaemia, 120, 303
1-methylxanthine, 238
Methylxanthines, 557
Metoclopramide, 51, 641
Metoprolol, 504
Metronidazole, 621
Mexiletine metabolism, 459
Microsomal metabolism, 741
Mild asthma, 512
Milk, 527, 751
Minimum inhibitory concentration, 621
Minocycline, 402
Molsidomine, 399
Monoacetyldapsone, 289
Mood, 347, 541
Multiple plasma peaks, 691
Muscle fatigue, 201
Myocardial infarction, 3

N-acetylation, 467
N-acetylglucosaminidase, 495
2-*n*-octadecyl indole-5-carboxylic acid, 655P
Nalidixic acid, 39
Naloxone, 611
Nasal vasoconstrictors, 705
Nebulise, 111
Nephrotoxicity, 495
Nicardipine, 57, 433
Nicotinic acid, 473
Nicotinuric acid, 473
Nifedipine, 441, 519, 541
Nimodipine, 335
Nisoldipine, 379
Nitecapone, 130
Nitrendipine, 11
Non-steroidal anti-inflammatory drugs, 495
Norfluoxetine, 136
Normal distribution, 159
Noroxycodone, 516

Octreotide, 563
5-OH-propafenone, 527
Omeprazole, 569
Opioid agonist, μ, 633
Org 10172, 23
Oriental populations, 504
Oros, 573
Orosomucoid, 311
Ouabain, 758
Oxcarbazepine, 741
Oxidative metabolism, 221
Oxycodone, 516
Oxypurinol, 238

PAH clearance, 495
Pain, 665P

Pain measurement, 69
Pain relief, 251
Paracetamol, 143, 651P, 691, 765, 768
Parkinson's disease, 229
Parotid gland, 259
Paroxetine, 659P
Penciclovir, 658P
Pentobarbitone, 23
Performance, 541
Perindopril, 187
Perindoprilat, 193
Pessary, 621
Pharmaceutical industry, 155, 531, 671
Pharmacodynamics, 429, 519, 581, 677
Pharmacogenetics, 235, 504, 729
Pharmacokinetic, 648P
Pharmacokinetic interaction, 569
Pharmacokinetics, 11, 31, 39, 57, 124, 167, 181, 187, 193, 242, 255, 261, 323, 335, 355, 361, 399, 429, 516, 519, 581, 591, 605, 617, 639, 641, 649P, 653P, 655P, 656P, 658P, 668P, 677, 761
Phenobarbitone, 329
Phenotype, 135, 283
Phenotyping, 289
Phenylephrine, 705
Phenylpropanolamine, 705
Phenytoin, 741
Pindolol, 105
Pirenzepine, 666P
Piroxicam, 667P
Plasma, 611
Platelet activating factor, 85
Platelet activation, 127
Platelet aggregation, 181, 761
Poisoning, 143
Polymorphic metabolism, 283
Polymorphism, 135, 136, 235, 289
Population pharmacokinetics, 669
Positron-emitting isotopes, 167
Posture, 138
Potassium, 630
Pravastatin, 127, 417
Pregnancy, 523
Premature newborn, 31
Primary anorexia nervosa, 685
Probenecid, 63, 489
Prochlorperazine, 455, 677
Prolactin, 51, 355, 483
Propafenone, 527
Propranolol, 105, 201, 581
Prostaglandin E_2, 77
Prostaglandins, 495
Protein binding, 311, 317
Psychological performance, 669P
Psychomotor performance, 341
Psychomotor tests, 455
Psychotropic effects, 91

QT interval, 429
Quinapril, 393, 648P
Quinine, 311, 317, 617
Quinolone, 124

RG 12525, 512
RP 54275, 655P
Ranitidine, 260, 519
Raynaud's phenomenon, 209
Receptive fields, 551
Relative maternal dose, 751
Remnoxipride, 355
Renal and biliary clearance, 63
Renal function, 261, 495
Renal haemodynamics, 387, 667P
Renal impairment, 57
Repeated doses, 242
Reproducibility, 275
Rifampicin, 735
Ropinirole, 483

SK&F 101468, 483
Saccadic eye movements, 666P
Safety, 361
Salbutamol, 637
Saliva, 259
Salivary flow, 666P
Semisolid meal, 685
Sensitivity, 551
Serum protein binding, 501
Simvastatin, 423
Single photon emission tomography, 229
Skin, 367
Slow release formulations, 473
Sodium metabisulphite, 637
Sodium valproate, 653P
Spatio-temporal contrast, 551
Spiradoline (U-62066E), 611
Spontaneous reporting, 407
Stable isotope, 573
Steady state, 761
Stereoselective, 735
Stereoselectivity, 11, 508
Steroid hormones, 417
Strontium, 441
Study adherence, 409
Sucralfate, 642
Sulphapyridine toxicity, 303
Sulphasalazine metabolism, 303
Sulphation, 768
Sumatriptan, 581
Sustained release, 433

Tenoxicam, 495
Terazosin, 775
Terbutaline, 630
Terfenadine, 371
Test battery, 669P
Theophylline, 124, 238, 341
Thermography, 209
Thiopurine methyltransferase, 729
Thromboxane, 77
Thromboxane A_2, 127
Thromboxane receptor blockade, 181
Ticlopidine, 761
Tissue ACE, 193
Tissue preparation, 402
Tolerance, 111
Toxicity, 717, 741
Transplantation, 323
Transpulmonary, 193
Transthoracic electrical bioimpedance, 275, 646P
Triamterene, 630
Trospectomycin, 255
Tyramine, 130
[Tyr-D-Arg-Gly-Phe (4-NO_2)-Pro-NH_2] 443C81, 663P, 664P

U-46619, 181
U-62,066E, 652P
UDP-glucuronosyltransferase, 765
UK-52,046, 599, 605
Ulcerative colitis, 248

Vapiprost, 181
Vascular reactivity, 758
Vascular smooth muscle, 523
Vasopressin, 611
Visual analogue, 341
Volunteers, 91, 141, 275

Warfarin, 508
Weal, 85
Whole body counting, 167
Whole-gut transit time, 248
Working blood pressure, 115

Ximoprofen, 242

Zidovudine, 17